AUTHORS
Ingridy Sodre da Costa Bonfim, MS, Syed Mahamad, MSc2, Na Li3, Rachael Grace, MMSc, MD4, Donald Arnold, MD5, Emily Marie Harris, MD6
AFFILIATIONS
1 Boston Children's Hospital, Boston, Massachusetts, United States, Università di Pavia, Pavia, Italy
2 McMaster University, Hamilton, Ontario, Canada
3 University of Calgary, Calgary, Alberta, Canada
4 Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, United States, Harvard Medical School, Boston, Massachusetts, United States
5 McMaster University, Hamilton, Ontario, Canada
6 Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, United States, Harvard Medical School, Boston, Massachusetts, United States
ABSTRACT
Background
Immune thrombocytopenia (ITP) remains a diagnosis of exclusion because there is no definitive laboratory test to distinguish ITP from other causes of thrombocytopenia. The platelet variability index (PVI) is a measure that captures both the fluctuations in platelet count measurements and the severity of the thrombocytopenia over time using at least three platelet counts. The PVI score is a categorical classification developed to support the diagnosis of ITP in adults (Li et al Blood Advances 2021). Whether the PVI score can distinguish ITP from non-immune thrombocytopenia in children is unknown.
Objective
To evaluate PVI in children with immune and non-immune thrombocytopenia.
Methods
This retrospective single-center cohort study included 285 pediatric patients with thrombocytopenia. Inclusion criteria were age ≤ 18 years, at least one platelet count <100 ×10⁹/L, and at least three platelet count measurements available in the medical record. Patients were considered to have ITP or non-immune thrombocytopenia based on ICD-10 code and clinical diagnosis documented by a hematologist in clinical notes the electronic medical record. The PVI score (from 0-6) was retrospectively calculated for each patient using platelet counts collected within 12 months following ITP diagnosis. Mann-Whitney tests were used to compare PVI scores between groups and Fischer’s exact test was used to evaluate sensitivity and specificity of high PVI score, defined as 5 or 6. The PVI thresholds developed for use in adults were applied directly to the pediatric population without modification. Use of the PVI authored by Donald M Arnold and Na Li, et al. was made under license from McMaster University, Hamilton, Canada.
Results
The final cohort consisted of 199 patients with ITP and 86 patients with non-immune thrombocytopenia, including Wiskott-Aldrich syndrome (n=21), hypersplenism (n=13), familial thrombocytopenia (n=8), aplastic anemia (n=6), Jacobsen syndrome (n=5), Fanconi anemia (n=3), Bernard-Soulier syndrome (n=3), and Shwachman-Diamond syndrome (n=2). Among children with ITP, 14.6% (n=29) had secondary ITP including 10 patients with Evans syndrome and 3 with lupus. The median number of platelet count measurements used to calculate PVI score was 5 (interquartile range: 4 – 8). There was no difference in time from first to last platelet count used for PVI score calculation between patients with ITP as compared to non-immune thrombocytopenia (median 203 vs 212 days). The average platelet count was higher in patients with ITP than non-immune thrombocytopenia (103 vs 52 x109/L, p<0.0001), reflective of disease resolution over time in many children with ITP.
Patients with ITP had higher PVI scores than patients with non-immune thrombocytopenia (median PVI score 5 vs 2, p<0.0001). High PVI scores (5-6) were observed in 132 of 199 patients (66.3%) with ITP and none of the 86 patients with non-ITP thrombocytopenia. High PVI score had a sensitivity of 66.3% (95% confidence interval (CI) 0.60-0.72) and specificity of 100% (95% CI: 0.96-1.0) for ITP.
PVI scores were not different between patients with primary versus secondary ITP (p=0.45). However, PVI score distribution differed significantly between groups based on treatment status and disease chronicity. Patients who received pharmacotherapy within a year of diagnosis (n=102) had higher PVI scores than those managed with observation alone (n=97) (p<0.0001). Among patients who received pharmacotherapy, 80.4% (82/102) had a high PVI score versus 51.5% (50/97) of those managed with observation alone. Patients who achieved remission within one year following diagnosis (n=137) had higher PVI scores than those with chronic ITP (n=56) (p=0.02). High PVI score was found in 71.5% (98/137) of those who achieved remission within one year as compared to 53.6% (30/56) of those with chronic ITP. However, children with chronic ITP still had higher PVI scores than children with non-immune thrombocytopenia (median 5 vs 2, p<0.0001).
Conclusion
Children with ITP had higher PVI scores than those with a wide variety of non-immune causes of thrombocytopenia. This suggests the clinical utility of the PVI tool in the evaluation of pediatric thrombocytopenia. The finding that children who achieved remission within one year had higher PVI scores may indicate that PVI also reflects disease behavior over time.
DISCLOSURES
Ingridy Sodre da Costa Bonfim, MS: No relevant conflicts of interest to declare.